- Journalists Capsulize Weight Loss News and ACA Premium Pressures
- BJC executives: Key questions shaping value-based care strategy
- Michael Dowling: Time to hold social media platforms accountable for the youth mental health crisis
- California county breaks ground on $23.7M behavioral health center
- Rhode Island hospital birthing center to remain open amid funding push
- Rhode Island hospital birthing center to remain open amid funding push
- OHSU CEO out after 3 months
- Arkansas system names CEO
- Sanford Health CIO steps into new role
- What increased hygienist autonomy means for dentistry
- COVID vaccination rates rise among healthcare workers: CDC
- More medical schools swap lectures for active learning
- 43 recent hospital, health system executive moves
- NorthBay receives $14.9M for new behavioral health center
- Buffalo Bills, Kaleida Health extend naming rights partnership
- The specialty facing a million dollar gender pay gap
- 10+ new cardiology practice openings in Q1
- 27 hospitals closing departments or ending services
- WHO updates opioid treatment, overdose guidance
- Michigan dentist charged with racketeering, Medicaid fraud
- CommonSpirit, Cigna reach agreement for Tennessee, Georgia
- Vermont Dental Society, U of Detroit to open state’s largest dental clinic
- How 5 specialties’ pay has changed over 5 years
- The anesthesia staffing strategies that are actually working
- CMS Innovation Center spent $7.9B in 1 decade: 7 notes
- How Medicaid Contractors Stand To Gain From Trump’s Policy
- Ohio hospital to pay $1.7M to resolve Stark law allegations
- HonorHealth margin dropped to -0.2% in 2025
- Idaho to restore Medicaid mental health programs after cuts
- ADA wary of impact CMS’ antifraud program could have on dentistry
- What’s new with Tenet?
- Federal agencies to revise mental health parity rule
- Inside SALT Dental Partners’ growth spurt
- Centerstone receives $750K VA suicide prevention grant
- Utah physician indicted for selling unapproved drugs
- Breaking Barriers: How Innovation Can Expand Access to Dental Care
- Lee Health breaks ground on 60K-square-foot ASC, MOB
- 15 big dental technology, AI updates to know from Q1
- Gastro Health inks deal with Virginia practice
- Montana hospital launches ASC expansion project
- Centene subsidiary to invest $6M in California behavioral health campus
- Moody’s upgrades Wellstar’s credit rating
- 5 dental mergers, acquisitions in March
- 4 DSOs making headlines
- CMS pitches payment rules for 4 care settings: 12 notes
- Public prior authorization data short on insight: KFF
- USDA Warns of Lead Risk in Frozen Dino-Shaped Chicken Nuggets
- New Heart Diet Advice Counters U.S. Guidance on Meat and Dairy
- Peeled Garlic Recalled Over Risk of Deadly Botulism
- Some CDC Lab Testing Paused Amid Internal Review
- White House floats 12.5% budget cut for HHS in FY2027, reiterates reorganization plan
- Boston Scientific receives FDA clearance for the Asurys Fluid Management System
- Boston Scientific receives FDA clearance for the Asurys Fluid Management System
- Serenity Medical Receives FDA Humanitarian Device Exemption for IIH Venous Stent
- Serenity Medical Receives FDA Humanitarian Device Exemption for IIH Venous Stent
- Blue Shield of California’s virtual-first plan continues to show lower costs, increased access for members
- Merit Medical Acquires View Point Medical, Inc., expanding the Merit Therapeutic Oncology Portfolio
- Merit Medical Acquires View Point Medical, Inc., expanding the Merit Therapeutic Oncology Portfolio
- FDA Publishes New Set of Real-World Evidence Examples
- FDA Publishes New Set of Real-World Evidence Examples
- Industry Voices—Hospitals are fueling AI innovation, should they own a piece of it?
- Nerve Stimulation Therapy May Ease Fibromyalgia Pain, Fatigue
- Psychotherapists Often Poorly Trained in Treating Muscle-Linked Disorders in Males
- Missing From Most Doctor-Patient Talks: Sleep Issues
- Plastics Chemical Linked To Nearly 2 Million Preterm Births Each Year
- Most Americans Don't Realize Brain Donation Is Needed to Study Autism
- Weekend Binge Drinking Triples Risk of Permanent Liver Damage
- Tax Time Brings Surprises for Some Who Receive ACA Subsidies
- An update on the pharma industry’s reshoring effort
- Listen: What the Vaccine Schedule Whiplash Means for Your Kids
- Biopharma R&D pipeline shrinks for 1st time in 30 years: report
- Lovelace closes New Mexico clinic 1 year post-acquisition
- Health systems on average aren’t breaking even
- UConn Health to acquire children’s psychiatric facility
- What the Health? From KFF Health News: GOP Mulls More Health Cuts
- Fierce Pharma Asia—Trump’s 100% drug tariff; Takeda layoffs; Lilly, Insilico's AI deal
- CMS locks in MA star ratings overhaul, bumps proposed special enrollment window for provider terminations
- Oregon university launches dental therapy program
- Trump slaps 100% duties on imported drugs but leaves plenty of exceptions
- OSU Wexner Medical Center reports 25% drop in safety incidents: 5 notes
- Novo Nordisk launches discounted subscription program for Wegovy through telehealth providers
- How the Harris Center navigates 70 contracts to fund a continuum of care
- GAO audit outlining CMMI's limited model scale-ups draws more Republican scrutiny
- UK signs off on US pharma deal, ensuring tariff reprieve as Britain aims to reattract investments
- BioNTech telegraphs closure of Singapore vaccine facility amid efforts to 'align capacity'
- FDA Recalls Wawa Milk Over Possible Plastic Contamination
- Wegovy Maker Launches Lower-Cost Subscription Plans
- FDA Approves New Weight Loss Pill, Foundayo, in Record Time
- Corti releases agentic model for medical coding, says it outperforms OpenAI, Anthropic
- Rising Stars: The Trade Desk's Elizabeth Keenan finds the rhythm in music and media
- Lawsuit Over Viral David Protein Bars Dropped Without Explanation
- Despite better cash flow, providers missed out on more revenue in 2025 due to increased payer denials
- Lawmakers introduce bipartisan legislation to help struggling rural hospitals stay open
- Lilly's obesity pill Foundayo gains early blockbuster forecast as analysts float 5M+ prescriptions in 2026
- Trump eyes 100% tariff rate for companies that have not struck MFN deals: Bloomberg
- Poland, Romania must pay Pfizer $2.2B in fight over contested COVID vaccine doses: Belgian court
- New Rapid Urine Test Could Revolutionize Treatment of UTIs
- New Pill Could Change Plaque Psoriasis Treatment
- Researchers Explore When Crying Helps You
- Burnout Driving Family Doctors to Quit Medicine, Study Finds
- Siblings Crucial To Middle-Aged People Grieving The Loss Of A Parent, Study Says
- Pandemic Spurred Increase In Screen Time Among Children, Teens
- Another AstraZeneca Emerald glimmers as Imfinzi, Imjudo delay liver cancer progression
- Family building platform Sunfish launches AI-powered egg freezing program with cost guarantee
- US Scientists Sequence 1,000 Genomes From Measles, a Disease Long Eliminated With Vaccines
- State-Run Insurance Plans for Foster Kids Leave Some of Them Without Doctors
- German CDMO Adragos buys French sterile injectables plant from Sanofi
- Glenmark goes direct with new US Ryaltris marketing plan as it drops partner model
- Bayer rejigs marketing claims after recommendation from US advertising body
- Intuition Robotics secures Medicaid coverage for social AI robot ElliQ in Washington State
- Memorial Hermann Health System, Blue Cross Blue Shield of Texas fail to reach contract deal
- Johns Hopkins Medicine, American Telemedicine Association launch cross-state telehealth initiative
- After Man’s Death Following Insurance Denials, West Virginia Tackles Prior Authorization
- 131 hospitals sue HHS over 2023 rule on Disproportionate Share Hospital calculation
- 4 out of 10 family physicians report feelings of burnout, Weill Cornell Medicine study finds
- Hundreds of U.S. Hospitals at Risk of Shutting Down From Medicaid Cuts
- Honey Almond Cream Cheese, Sold at Einstein Bros. Bagels, Recalled Due To Undeclared Nuts
- Trump Supports Surgeon General Pick Despite Senate Concerns
- A look at AMA's Joy in Medicine program amid steady physician burnout rates
- Lilly answers Novo's GLP-1 pill with highly anticipated FDA nod for Foundayo
- Supreme Court Blocks Colorado Limits on Therapy for LGBTQ Minors
- Hospital groups call on Congress to refine long-term care hospital payments
- Study Shows BMI Often Gets Your Weight Category Wrong
- Antidepressant, Fluvoxamine, Might Help Long COVID Fatigue, Study Says
- Kinesio Taping’s Benefits in Doubt, Major Evidence Review Finds
- High Sodium Intake May Trigger New Heart Failure
- Home-Delivered Groceries Boost Heart Health In Food Deserts, Study Says
- Nicotine E-Cigarettes Help Smokers Quit, Review Concludes
- Clinicians are burnt out. Peer support can help
- Novo's Wegovy nets cardio nod from UK cost gatekeeper, adding 1M+ eligible patients
- Trump’s One Big Beautiful Bill Act Darkens Outlook for Government-Backed Clinics
- Readers Sound Off on Wage Garnishment, Work Requirements, and More
- CVS Health opens pharmacy-only locations as it rightsizes store footprint
- How Rural Health Systems Are Advancing Cardiac Imaging
- How Rural Health Systems Are Advancing Cardiac Imaging
- Beyond Reimbursement: Why Market Access is MedTech’s Strategic North Star
- Beyond Reimbursement: Why Market Access is MedTech’s Strategic North Star
- Evotec hires exec with AI experience to lead rebooted commercial team
- The Human Side of AI Medical Devices: Why Safety Depends on Design, Not Just Algorithms
- The Human Side of AI Medical Devices: Why Safety Depends on Design, Not Just Algorithms
- Whoop raises $575M series G, Abbott comes on board amid hiring spree
- ‘There isn't as much meat left to cut’: Biopharma layoffs maintain slowdown in Q1
- Bipartisan bill introduced to stabilize physicians' year-to-year pay changes
- UnitedHealthcare launches Avery, a generative AI companion for members
- FDA flags serious liver injury cases, 8 deaths with ‘reasonable’ link to Amgen's Tavneos
- Novo Nordisk cuts 400 roles at troubled Bloomington site
- Former U.S. Surgeon General Challenges Trump Nominee
- Iterum initiates wind-down after failure to offload antibiotic with sluggish sales
- Over 10.2 Million Grill Brushes Recalled Over Metal Bristle Risk
- Sex Enhancement Chocolates Recalled Over Hidden Drug Ingredients
Not exactly over-the-counter, actually pharmacist prescribed birth control pills:
Over-the-counter birth control hitting shelves, thanks to Michigan firm
- The FDA decided last year that a longtime birth control pill was safe enough to gain over-the-counter status.
- The drug, Opill, is the product of a Grand Rapids-based company which has headquarters in Ireland, too.
- The pill began shipping Monday at a cost of $20 a month, or $50 for a three-month supply.
By Robin Erb - March 4, 2024
The first over-the-counter daily birth control pill began shipping to pharmacies Monday, dramatically boosting convenience and access among oral contraceptives, especially for low-income women, those living in rural areas and those without easy access to transportation or child care.
On Monday, Opill — which is offered in a 28-day blister pack and is 98% effective against unplanned pregnancies when taken as directed — became available for the first time nationally.
It is the product of drugmaker Perrigo, which is based both in Grand Rapids and Ireland.The drug is being manufactured in Ireland, and its active ingredient, norgestrel, is being manufactured in Germany.
After months of anticipation by medical groups and consumer groups, the company announced the first, long-awaited shipments Monday morning.
“It’s revolutionary in terms of having women take control of their reproductive choices,” said Dr. Ann Gillett-Elrington, a staff physician and board-certified obstetrician at Western Wayne Family Health Centers.
The suggested retail price will be $20 for a one-month supply, $50 for a three-month supply and $90 for a six-month supply.
The relatively low cost is good news, especially for the uninsured or without regular medical care, she said.
“Appointments — sometimes they're far in between. People can get pregnant in the interval,” she said. “They also have to take time off from work (for an appointment) and they might have to make child arrangements.”
Given the cost of those things or an unplanned pregnancy, the pill “is very cost-effective,” she said.
The pill will be available at major retail pharmacies, including Walgreens and CVS, and through Amazon, said Perrigo’s chief commercial officer, Sara Young, who called the pill “groundbreaking.”
The French drugmaker HRA Pharma had begun seeking FDA approval for its over-the-counter product when Perrigo purchased the company in a sale completed in 2022.
Opill will also be sold online directly to consumers from opill.com on March 18, she said.
Long awaited
The U.S. Food and Drug Administration switched Opill, a progestin-only tablet, to an over-the-counter drug in July. Because it doesn’t contain the hormone estrogen, it may have few side effects. Most common side effects are irregular bleeding, headaches, dizziness, nausea, increased appetite, abdominal pain, cramps or bloating, according to the FDA’s July announcement.
The drug had originally been approved in 1973. In making its decision last year, the FDA made it clear that the pill was safe and effective enough that Americans could decide on their own — with consulting with a doctor — whether Opill is appropriate for them.
That’s “obviously a very important step forward regarding convenience and access,” said Dr. Mark Fendrick, an internal medicine doctor and director of the Center for Value-Based Insurance Design at the University of Michigan.
About 26 million Americans are uninsured, according to the U.S. Census, making it difficult or too expensive to get regular medical care, he said.
Family planning, including options for oral contraception, is “a very effective, equitable and important public health and population health measure,” he said, so Opill is a “great step forward for access.”
Moreover, limitations or bans on abortion in some states make pregnancy prevention even more critical.
For its part, Right to Life of Michigan, aligning with national leaders of Right to Life, takes no position on products that prevent an egg’s fertilization, legislative director Genevieve Marnon, told Bridge Michigan, Monday.
Still unknown is whether insurers, including the state’s Medicaid program, will cover the costs of the pill.
The pill likely will show up at local pharmacies later this month, said Farah Jalloul, state emergency preparedness coordinator at the Michigan Pharmacists Association. And pharmacies can decide whether they will carry the pill, she noted, though she added that most undoubtedly will do so.
When it hits the shelves, it will be available to consumers of any age — a concern for some who worry about adolescents or some adults who might be unable to follow directions or understand contraindications.
Among those who should not take Opill are women with a history of breast cancer. People who have any other form of cancer should consult their doctor before taking Opill. And Opill is not for use as emergency contraception nor does it prevent sexually transmitted infections.
Ideally, said Gillett-Elrington at Western Wayne Family Health Centers, a young person or an adult with questions will talk with a trusted medical professional before taking Opill, though there are no guarantees, she acknowledged.
The drug works mainly by thickening a person’s cervical mucus, thereby blocking sperm from reaching the egg. Opill also may prevent an egg from implanting or altogether block its release from the ovaries. But a pill from the 28-day blister pack must be taken every day.
More than one in three women using oral contraceptives (36%) had missed taking doses because they were unable to get their next supply, according to a 2022 KFF Women’s Health Survey.Medical groups, including the American Medical Association, had urged the FDA to approve over-the-counter daily contraception. And the American College of Obstetricians and Gynecologists Monday lauded the release, and released guidelines for clinicians.
ACOG President Dr. Verda J. Hicks, called Opill a safe drug for patients of all ages, including adolescents.
It’s a “key component of reproductive health care” in a country where there are “increasing healthcare deserts … where people do not have access to gynecologic care,” she said in a prepared statement.
Despite some initial concerns that consumers might not be able to understand how to take the pills or why some patients should not take the pills, ACOG doctors “trust our patients to determine if this OTC method is best for them.”
Perrigo executed a corporate tax inversion to Ireland eleven years ago to avoid U.S. corporate taxes. It was 'acquired' by Irish-based Elan Corporation for $ 8.6 billion. The combined company is now known as Perrigo Company plc.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.



















